JOURNAL OF CLINICAL ONCOLOGY

SPECIAL ARTICLE

Т

Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation

Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Frank Alvaro, Fabianne Carlesse, Brian Fisher, Hana Hakim, Maria Santolaya, Elio Castagnola, Bonnie L. Davis, L. Lee Dupuis, Faith Gibson, Andreas H. Groll, Aditya Gaur, Ajay Gupta, Rejin Kebudi, Sérgio Petrilli, William J. Steinbach, Milena Villarroel, Theoklis Zaoutis, and Lillian Sung

Processed as a Rapid Communication manuscript

A B S T R A C

Purpose

To develop an evidence-based guideline for the empiric management of pediatric fever and neutropenia (FN).

Methods

The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group composed of experts in pediatric oncology and infectious disease as well as a patient advocate. The Panel was convened for the purpose of creating this guideline. We followed previously validated procedures for creating evidence-based guidelines. Working groups focused on initial presentation, ongoing management, and empiric antifungal therapy. Each working group developed key clinical questions, conducted systematic reviews of the published literature, and compiled evidence summaries. The Grades of Recommendation Assessment, Development, and Evaluation approach was used to generate summaries, and evidence was classified as high, moderate, low, or very low based on methodologic considerations.

Results

Recommendations were made related to initial presentation (risk stratification, initial evaluation, and treatment), ongoing management (modification and cessation of empiric antibiotics), and empiric antifungal treatment (risk stratification, evaluation, and treatment) of pediatric FN. For each recommendation, the strength of the recommendation and level of evidence are presented.

Conclusion

This guideline represents an evidence-based approach to FN specific to children with cancer. Although some recommendations are similar to adult-based guidelines, there are key distinctions in multiple areas. Implementation will require adaptation to the local context.

J Clin Oncol 30. © 2012 by American Society of Clinical Oncology

INTRODUCTION

Fever and neutropenia (FN) are common complications in children who receive chemotherapy for cancer. Although several guidelines for the management of FN have been developed,¹⁻⁷ none are dedicated to children. FN guidelines specifically focused on children with cancer are important.⁸ To address this critical gap, we convened a panel of pediatric cancer and infectious disease experts, as well as a patient advocate, to develop an evidence-based guideline for the empiric management of pediatric FN.

METHODS

The International Pediatric Fever and Neutropenia Guideline Panel included representatives from oncology, infectious disease, nursing, and pharmacy, as well as a patient advocate, from 10 different countries (Data Supplement 1). Participants (other than the patient advocate) were selected based on peerreviewed publications in pediatric FN while considering balance by geography.

We followed previously validated procedures for creating evidence-based guidelines⁹ and used the Appraisal of Guidelines for Research and Evaluation

© 2012 by American Society of Clinical Oncology 1

Author affiliations appear at the end of this article.

Submitted March 1, 2012; accepted July 13, 2012; published online ahead of print at www.jco.org on September 17, 2012.

Supported by Meeting Grant No. 243795 from the Canadian Institutes of Health Research. L.S. is supported by a New Investigator Award from the Canadian Institutes of Health Research.

T.L. and R.P. contributed equally to this work.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Lillian Sung, MD, PhD, Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G 1X8 Canada; e-mail: lillian.sung@ sickkids.ca.

© 2012 by American Society of Clinical Oncology

0732-183X/12/3099-1/\$20.00

DOI: 10.1200/JCO.2012.42.7161

II instrument as a framework.¹⁰ Members were divided into working groups that addressed each of the three major sections (initial presentation, ongoing management, and empiric antifungal therapy). Each working group developed the key clinical questions to be addressed by the guideline and identified and rated the importance of outcomes relevant to the questions on a 9-point scale (Data Supplement 2). Ratings of 7 to 9 indicated that the outcome was critical for a decision or recommendation; 4 to 6, that it was important; and 1 to 3, that it was not important. The median ratings from working group members established the importance of the outcomes and guided recommendations.

For each question, systematic reviews of the published literature were conducted until March 2011 (available on request), and each

working group compiled evidence summaries. Empiric treatments focused on pharmacologic interventions and did not include therapies such as growth factors. The Grades of Recommendation Assessment, Development, and Evaluation approach was used to generate summaries, and evidence was classified as high, moderate, low, or very low based on methodologic considerations.¹¹ Data Supplement 3 illustrates additional details of the guideline methodology.

RECOMMENDATIONS AND EXPLANATIONS

The summary of recommendations is listed in Table 1, and the associated evidence profiles are illustrated in Data Supplements 4 to 10.

Table 1. Overall Summary of Recommendations*									
Initial Presentation of FN									
Risk Stratification	Evaluation	Treatment							
Adopt a validated risk stratification strategy and incorporate it into routine clinical management (1C)	 Obtain blood cultures at onset of FN from all lumens of central venous catheters (1C) Consider peripheral-blood cultures concurrent with obtaining central venous catheter cultures (2C) Consider urinalysis and urine culture in patients where clean-catch, midstream specimen is readily available (2C) Obtain chest radiography only in symptomatic patients (1B) 	 High-risk FN: Use monotherapy with antipseudomonal β-lactam or carbapenem as empiric therapy in pediatric high-risk FN (1A) Reserve addition of second Gram-negative agent or glycopeptide for patients who are clinically unstable, when resistant infection is suspected, or for centers with high rate of resistant pathogens (1B) Low-risk FN: In children with low-risk FN, consider initial or step-down outpatient management if infrastructure is in place to ensure careful monitoring and follow-up (2B) In children with low-risk FN, consider oral antibiotic administration if child is able to tolerate this route of 							
Ongoing Management of FN: ≥ 24 to 72 Hours After Initiation of Empiric Antibacterial Treatment									
	Modification of Treatment	Cessation of Treatment							
	 In patients who are responding to initial empiric antibiotic therapy, discontinue double coverage for Gram-negative infection or empiric glycopeptide (if initiated) after 24 to 72 hours if there is no specific microbiologic indication to continue combination therapy (1B) Do not modify initial empiric antibacterial regimen based solely on persistent fever in children who are clinically stable (1C) In children with persistent fever who become clinically unstable, escalate initial empiric antibacterial regimen to include coverage for resistant Gram-negative, Grampositive, and anaerobic bacteria (1C) 	 All patients: Discontinue empiric antibiotics in patients who have negative blood cultures at 48 hours, who have been afebrile for at least 24 hours, and who have evidence of marrow recovery (1C) Low-risk FN: Consider discontinuation of empiric antibiotics at 72 hours in low-risk patients who have negative blood cultures and who have been afebrile for at least 24 hours, irrespective of marrow recovery status, as long as careful follow-up is ensured (2B) 							
	Empiric Antifungal Treatment: \geq 96 Hours After Initiation	of Empiric Antibacterial Treatment							
Risk Stratification	Evaluation	Treatment							
Patients at high risk of IFD are those with AML or relapsed acute leukemia, those receiving highly myelosuppressive chemotherapy for other malignancies, and those undergoing allogeneic HSCT with persistent fever despite prolonged (≥ 96 hours) broad- spectrum antibiotic therapy and expected prolonged neutropenia (> 10 days); all others should be categorized as IFD low risk (1B)	 All patients: Consider galactomannan in bronchoalveolar lavage and cerebrospinal fluid to support diagnosis of pulmonary or CNS aspergillosis (2C) In children, do not use β-D-glucan testing for clinical decisions until further pediatric evidence has accumulated (1C) IFD high risk: Consider prospective monitoring of serum galactomannan twice per week in IFD high-risk hospitalized children for early diagnosis of invasive aspergillosis (2B) In IFD high-risk children with persistent FN beyond 96 hours, perform evaluation for IFD; evaluation should include CT of lungs and targeted imaging of other clinically suspected areas of infection (1B); consider CT imaging of sinuses in children ≥ 2 years of age (2C) IFD low risk: In IFD low-risk patients, do not implement routine galactomannan screening (1C) 	 All patients: Use either caspofungin or liposomal amphotericin B for empiric antifungal therapy (1A) IFD high risk: In neutropenic IFD high-risk children, initiate empiric antifungal treatment for persistent or recurrent fever of unclear etiology that is unresponsive to prolonged (≥ 96 hours) broad-spectrum antibacterial agents (1C) IFD low risk: In neutropenic IFD low-risk children, consider empiric antifungal therapy in setting of persistent FN (2C) 							

*Parentheses indicate GRADE strength of recommendation (1, strong; 2, weak) and quality of evidence (A, high; B, moderate; C, low or very low).

2 © 2012 by American Society of Clinical Oncology

Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 AmericanfiSoci6420fSDline@BOncology. All rights reserved. Identified research gaps and recommendations for future research are listed in Table 2.

SECTION 1: INITIAL PRESENTATION OF FN

Question

What clinical features and laboratory markers can be used to classify pediatric patients with FN as being at low or high risk for poor outcomes?

Recommendation

Adopt a validated risk stratification strategy (Table 3) and incorporate it into routine clinical management (1C; strong recommendation, low-quality evidence).

Explanation

Studies of risk prediction in children include retrospective and prospective observational cohort studies that vary in inclusion criteria, specific definitions of FN, and exact outcomes measured.^{12-17,20,21,23-33} Studies of risk assessment in adult FN populations were not included in recommendation formulation.⁸

Common elements informative for risk stratification included patient-specific factors (including age, malignancy type, and disease status), treatment-specific factors (type and timing of chemotherapy), and episode-specific factors (including height of fever, hypotension, mucositis, blood counts, and C-reactive protein [CRP]). The schemas uniformly exclude those with more severe myelosuppression and patients undergoing hematopoietic stem-cell transplantation (HSCT) from low-risk definitions. They are also consistent with the largely adult-focused Infectious Diseases Society of America guideline,¹ but in pediatric studies, the depth of thrombocytopenia or leukopenia has been examined rather than anticipation of

	Table	FN	
--	-------	----	--

Identification of a validated high-risk stratification schema for pediatric fever and neutropenia
Determination of the incremental value of a peripheral-blood culture in addition to central venous catheter cultures of an adequate volume in children with FN
Identification of the optimal type and frequency of re-evaluation (for example, daily or every second day telephone contact or clinic visit) for pediatric outpatients with low-risk FN
Determination of the optimal treatment regimen for microbiologically documented sterile site infections during FN
Identification of the optimal frequency of blood culture sampling in persistently febrile pediatric patients with neutropenia who are either clinically stable or unstable
Determination of the optimal duration of antibiotic therapy for patients with high-risk FN without bone marrow recovery for prolonged periods
Determination of whether a strategy of routine galactomannan screening in IFD high-risk children is cost-effective and results in better clinical outcomes compared to a strategy without screening
Determination of the clinical utility and optimal cut-off of β -D-glucan testing in IFD high-risk children
Determination of the clinical utility of routine sinus imaging in children being evaluated for IFD
Determination of the safety and efficacy of a preemptive antifungal approach in IFD low-risk and IFD high-risk children
Identification of the optimal investigation and treatment for viral infections in children with FN

Abbreviations: FN, fever and neutropenia; IFD, invasive fungal disease.

prolonged neutropenia in predicting which patients are at higher risk of experiencing complications.

Six low-risk stratification schemas have been validated in different pediatric populations (Table 3). Evaluation of these studies does not allow the recommendation of a single low-risk prediction rule, because no single rule is clearly more effective or reliable than the others, nor does it allow us to convincingly recommend different rules for predicting specific outcomes.³⁴ It is important to recognize that the process of deriving prediction rules frequently overestimates their effectiveness in practice, so rules require validation. Furthermore, geographic and temporal validation are important, because differences in local practices, systems, and approaches may alter how the rules perform.³⁵

The rule developed by Santolava et al,¹⁵ derived from Chile, was shown to be highly effective when used in the same population.³⁶ Similarly, the rule of Alexander et al¹³ from Boston has been effectively used in England¹⁹ and implemented in Canada. Consequently, clinicians in Chile would be justified in using the Santolaya et al rule, whereas those in England, Canada, and the United States could reasonably implement the rule of Alexander et al. The choice of strategy may also be influenced by the ability of an institution to implement more complex rules and the timeliness of receipt of test results such as CRP. Each institution should maintain records of which specific strategy is used and evaluate the performance of the chosen rule to ensure accuracy and safety within a specific clinical setting. Identification of a predominant risk stratification schema for use across clinical trials and in clinical practice (where appropriate) would optimize future research and patient care. It is important to note that there are no validated schemas for defining those patients at high risk of developing complications from FN.

Question

What clinical, laboratory, and imaging studies are useful at the initial presentation of FN to assess the etiology of the episode and guide future treatment?

Recommendations

Obtain blood cultures at the onset of FN from all lumens of central venous catheters (CVCs; 1C; strong recommendation, lowquality evidence). Consider peripheral-blood cultures concurrent with obtaining CVC cultures (2C; weak recommendation, low-quality evidence). Consider urinalysis and urine culture in patients for whom a clean-catch, midstream specimen is readily available (2C; weak recommendation, low-quality evidence). Obtain chest radiography (CXR) only in symptomatic patients (1B; strong recommendation, moderate-quality evidence).

Explanation

The etiology of initial fever may be noninfectious, bacterial, or viral, or less commonly, it may result from other pathogens. Viral pathogens are common, and evaluation should be directed at specific signs and symptoms.

Blood culture. Blood cultures obtained during the evaluation of FN are essential. A majority of children with cancer receiving chemotherapy have an indwelling CVC; for these children, obtaining a blood culture of adequate volume from all lumens of the CVC is important. However, the utility of peripheral-blood cultures in addition to CVC

	(2010)	otherapy than ce	globin nts each J/L g/L	ow risk ', high	et al ²²	on; URTI,
	Ammann et al ¹⁷	4 points for chem more intensive ALL maintenan	5 points for hemc \geq 90 g/L; 3 poi for WBC < 300 platelets < 50 (Total score < 9, Iv of adverse FN outcome; HSC1 risk	Europe; Miedema (2011)	em-cell transplantati
	Ammann et al ¹⁶ (2003)	Bone marrow involvement, central venous catheter, pre-B-cell leukemia	Absence of clinical signs of viral infection, CRP > 50 mg/L, WBC ≤ 500 /uL, hemoglobin > 100 g/L	Three or fewer risk factors, low risk of significant infection; HSCT, high risk	Europe; Ammann et al ¹⁷ (2010); Macher et al ²¹ (2010)	ropenia; HSCT, hematopoietic st
trategies for Low-Risk Patients	Santolaya et al ¹⁵ (2001)	Relapsed leukemia; chemotherapy within 7 days of episode	CRP ≥ 90 mg/L, hypotension, platelets ≤ 50 g/L	Zero risk factors, only low platelets, or only < 7 days from chemotherapy, low risk of invasive bacterial infection	South America; Santolaya et al ²⁰ (2002)	rest radiograph; FN, fever and neut
ed Pediatric Risk Stratification St	Rondinelli et al ¹⁴ (2006)	2 points for central venous catheter; 1 point for age ≤ 5 years	4.5 points for clinical site of infection; 2.5 points for no URTI; 1 point each for fever $> 38.5^{\circ}$ C, hemoglobin $\leq 70 \text{ g/L}$	Total score < 6, low risk of serious infectious complication; HSCT, high risk	Brazil; Rondinelli et al ¹⁴ (2006)	CRP, C-reactive protein; CXR, ch lications.
Table 3. Validat	Alexander et al ¹³ (2002)	AML, Burkitt's lymphoma, induction ALL, progressive disease, relapsed with marrow involvement	Hypotension, tachypnea/hypoxia < 94%, new CXR changes, altered mental status, severe mucositis, vomiting or abdominal pain, focal infection, other clinical reason for inpatient treatment	Absence of any risk factor, low risk of serious medical complication; HSCT, high risk	United Kingdom; Dommett et al ¹⁹ (2009)	a; ALL, acute lymphoblastic leukemia iation of a group at low risk of comp
	Rackoff et al ¹² (1996)	None	Absolute monocyte count	Absolute monocyte count ≥ 100/uL, low risk of bacteremia; HSCT, high risk	United States; Madsen et al ¹⁸ (2002)	., acute myeloid leukemie act infection. iically adequate discrimin
	Strategy Factor	Patient- and disease related factors	Episode-specific factors	Rule formulation	Demonstrated to be valid*	Abbreviations: AMI upper respiratory tra "Valid refers to clin

4

JOURNAL OF CLINICAL ONCOLOGY

© 2012 by American Society of Clinical Oncology JOURNAL OF CLIN Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 Americanf Societ92 of Societ92 of

cultures is controversial. Seven studies evaluated concurrent peripheral and CVC cultures in adults and children with cancer and/or undergoing HSCT³⁷⁻⁴³ (Data Supplement 4). Only two studies removed probable contaminants from the analysis. Overall, the proportion of bacteremia detected by peripheral-blood cultures alone (ie, CVC cultures were negative) was 13% (95% CI, 8% to 18%). The designation of this recommendation as weak arises from balancing increased yield of bacteremia against pain/inconvenience and contaminants associated with peripheral cultures. Peripheral cultures may also help to diagnose catheter-related infections, although the clinical utility of the diagnosis is unclear.⁴⁴

Multiple variables can influence blood culture yield, including blood culture volume, choice of media type, number of culture bottles inoculated, and frequency of cultures.⁴⁵ Although an adequate volume of blood inoculated is important^{46,47} and often not consistently collected,⁴⁸ minimum volumes have not been established in pediatric patients. Manufacturer volume recommendations and weight-based sliding scales⁴⁹ are two approaches to standardizing volume of blood collected.

Urinalysis and urine culture. Urinary tract infections (UTIs) are common in pediatric FN.²⁰ Routine urinalysis and culture at the initial evaluation of FN in children is controversial. Restricting urine culture to those with symptoms or abnormal urinalysis is probably not justified in children. Pyuria was found in only 4% of UTI episodes during neutropenia, compared with 68% in control patients with cancer without neutropenia (P < .001).⁵⁰ Nitrite testing in younger children (without cancer) is also known to be less effective than in older patients.⁵¹

Given the concerns regarding delay of therapy and possibly increased adverse events associated with invasive methods for urine collection, the Panel recommends that where a clean-catch or midstream urine sample can be collected, it should be obtained before commencing antibiotics. Urine collection should not delay treatment.

CXR. A CXR had been advocated as part of the routine, initial assessment of pediatric FN, because the neutropenic child was believed to be less likely to exhibit signs and symptoms of pneumonia than the immunocompetent child.⁵² Four studies that included 540 episodes of FN⁵³⁻⁵⁶ examined the value of routine CXR; each found that the frequency of pneumonia in an asymptomatic child was 5% or less.⁵⁷ Asymptomatic children who do not receive a CXR had no significant adverse clinical consequences, ⁵⁶ and thus, routine CXRs are not recommended in asymptomatic children.

Question

What empiric antibiotics are appropriate for children with highrisk FN?

Recommendations

Use monotherapy with an antipseudomonal β -lactam or a carbapenem as empiric therapy in pediatric high-risk FN (1A; strong recommendation, high-quality evidence). Reserve addition of a second Gram-negative agent or glycopeptide for patients who are clinically unstable, when a resistant infection is suspected, or for centers with a high rate of resistant pathogens (1B; strong recommendation, moderate-quality evidence).

Explanation

Initial management of pediatric FN will be influenced by many factors, such as patient characteristics, clinical presentation, local infrastructure to support different models of care, drug availability and cost, and local epidemiology, including resistance patterns. In general, coverage should include Gram-negative organisms in all patients as well as viridans group streptococci and *Pseudomonas aeruginosa* in high-risk FN. The overall goal of empiric therapy is to provide coverage for virulent organisms while minimizing exposure to unnecessary antibiotics, because indiscriminant use of broad-spectrum antibiotics may accelerate antibiotic resistance rates.

Data Supplement 5 presents all published, English-language, prospective trials of pediatric FN evaluating a homogeneous initial empiric antibiotic strategy providing coverage appropriate for highrisk FN patients; combination regimens are included. Outcomes deemed clinically important by the Panel were synthesized by antibiotic type; no particular regimen was superior to another.

Two meta-analyses compared monotherapy versus an aminoglycoside-containing regimen in FN^{58} and in immunocompromised patients with sepsis⁵⁹; patients were primarily adults. The metaanalyses demonstrated noninferiority of monotherapy regimens and higher toxicity with combination regimens. The FN meta-analysis found fewer treatment failures with monotherapy (odds ratio [OR], 0.88; 95% CI, 0.78 to 0.99), but this analysis included only four trials that enrolled patients younger than 14 years of age.⁵⁸ A pediatric meta-analysis found that aminoglycoside-containing combination treatment did not improve clinical outcomes in comparison with antipseudomonal penicillin monotherapy.⁶⁰

Specific monotherapy regimens evaluated in children and presented in Data Supplement 5 include antipseudomonal penicillins (such as piperacillin-tazobactam and ticarcillin-clavulinic acid), antipseudomonal cephalosporins (such as cefepime), and carbapenems (meropenem or imipenem). No difference in treatment failure, mortality, or adverse effects was seen when antipseudomonal penicillins were compared with antipseudomonal cephalosporins or carbapenems.61,61 However, carbapenems may be associated with more pseudomembranous colitis in comparison with other B-lactam antibiotics.⁶² In terms of antipseudomonal cephalosporins, a metaanalysis of randomized controlled trials (RCTs) found a statistically significant increase in all-cause mortality in cefepime-treated versus other *β*-lactam-treated patients.⁶² However, this finding was refuted in a US Food and Drug Administration review,⁶³ and increased mortality was not observed in a pediatric meta-analysis.⁵⁶ Consequently, cefepime may be an appropriate initial empiric therapy for children with FN if local circumstances support its use. Ceftazidime monotherapy should not be used if there are concerns of Gram-positive or resistant Gram-negative infections.64

The role of empiric glycopeptides in FN was examined in a predominantly adult meta-analysis of 14 RCTs.⁶⁵ Inclusion of a glycopeptide led to less frequent treatment modification, but if addition of glycopeptides in the control arm was not considered failure, no difference in treatment success was seen (OR, 1.02; 95% CI, 0.68 to 1.52). However, adverse effects were more common in the empiric glycopeptide group.

Irrespective of empiric choices, rigorous epidemiologic surveillance is critical, and empiric antibiotic regimens should be regularly

© 2012 by American Society of Clinical Oncology 5

reviewed in light of evolving institutional microbial resistance patterns. Monotherapy may not be appropriate in institutions with a high rate of resistance.

Question

In children with low-risk FN, is initial or step-down outpatient management as effective and safe as inpatient management?

Recommendation

In children with low-risk FN, consider initial or step-down outpatient management if the infrastructure is in place to ensure careful monitoring and follow-up (2B; weak recommendation, moderatequality evidence).

Explanation

Outpatient management of children with FN is attractive, given the increased quality of life for children⁶⁶ and large reduction in costs⁶⁷ associated with an ambulatory approach. One meta-analysis of RCTs compared inpatient versus outpatient management of FN.⁶⁸ In six studies, outpatient management was not associated with significantly higher treatment failure (rate ratio [RR], 0.81; 95% CI, 0.55 to 1.28; P = .28), where RR < 1 favored inpatient care. There was no difference in mortality (RR, 1.11; 95% CI, 0.41 to 3.05; P = .83). In a stratified analysis of the two pediatric studies,^{69,70} results were similar to the overall analysis.

Data from 16 prospective trials of pediatric low-risk FN based on site of care within the first 24 hours are presented in Data Supplement 6.⁷¹ There was no increase in treatment failure (including modification) with outpatient relative to inpatient management (15% v 27%; P = .04). Importantly, there were no infection-related deaths among the 953 outpatients.⁷¹

Question

In children with low-risk FN, is initial or step-down oral antibiotic management as effective and safe as management with parenteral antibiotics?

Recommendation

In children with low-risk FN, consider oral antibiotic administration if the child is able to tolerate this route of administration reliably (2B; weak recommendation, moderate-quality evidence).

Explanation

Oral antibiotics may be advantageous, because they facilitate outpatient management and are generally less costly compared with parenteral antibiotics. However, oral medication administration may present major challenges in children. Issues include drug availability as an oral liquid, palatability, cooperation of young children, mucositis, and impaired gastrointestinal absorption. Two meta-analyses of RCTs compared oral and parenteral antibiotics for FN; one included all settings (n = 2,770),⁷² whereas the other was restricted to the outpatient setting (n = 1,595).⁶⁸ Both included all FN risk groups. They both showed no difference in treatment failure (including modification), overall mortality, or antibiotic adverse effects, either among all participants or when stratified among the pediatric subset. However, in the stratified analysis of five pediatric RCTs, oral outpatient management was associated with a higher rate of readmission compared

with parenteral outpatient management (RR, 0.52; 95% CI, 0.24 to 1.09; P = .08).⁶⁸

Prospective pediatric trial data comparing parenteral and oral antibiotic therapy initiated within 24 hours of treatment initiation in low-risk FN are presented in Data Supplement 7.⁷¹ Oral antibiotics used were fluoroquinolone monotherapy (seven studies; n = 581), fluoroquinolone and amoxicillin-clavulanate (three studies; n = 159), and cefixime (one study, n = 45). There were no differences in treatment failure (including modification) and no infection-related deaths among the 676 children administered oral antibiotics.⁷¹

SECTION 2: ONGOING MANAGEMENT OF FN, EXCLUDING EMPIRIC ANTIFUNGAL THERAPY

Question

When and how should the initial empiric antibiotic therapy be modified during the pediatric FN episode?

Recommendation

In patients who are responding to initial empiric antibiotic therapy, discontinue double coverage for Gram-negative infection or empiric glycopeptide (if initiated) after 24 to 72 hours if there is no specific microbiologic indication to continue combination therapy (1B; strong recommendation, moderate-quality evidence). Do not modify the initial empiric antibacterial regimen based solely on persistent fever in children who are clinically stable (1C; strong recommendation, low-quality evidence). In children with persistent fever who become clinically unstable, escalate the initial empiric antibacterial regimen to include coverage for resistant Gram-negative, Grampositive, and anaerobic bacteria (1C; strong recommendation, very low-quality evidence).

Explanation

Initial empiric antibiotics should be modified to include clinically or microbiologically documented infection. In patients who are responding to initial empiric antibiotic therapy in whom double Gramnegative coverage or empiric glycopeptide has been initiated (for example, because of clinical instability or concern about resistance), these additional antibiotics should be discontinued 24 to 72 hours after treatment initiation if there is no specific microbiologic indication to continue combination therapy. Early discontinuation is based on the rationale for initial monotherapy without the addition of aminoglycosides and empiric vancomycin as described earlier.

Empiric antibacterials should not be modified solely based on the persistence of fever in clinically stable patients; rather, modification should be based on clinical and microbiologic factors. For example, modification may occur on the basis of an evolving clinical site of infection, microbiology results including resistance profiles, or occurrence of hypotension or other signs of clinical instability. A double-blind RCT showed that the addition of vancomycin, compared with placebo, did not reduce the time to defervescence in neutropenic patients with cancer who had persistent fever 48 to 60 hours after the initiation of empiric piperacillin-tazobactam monotherapy.⁷³ However, only nine of 165 patients were children.

There are no trials evaluating the role of modifying initial empiric monotherapy in persistently febrile patients who become clinically unstable. The Panel recommends escalation of the initial

Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 Americanfr@ccie492df50lift982aB9ncology. All rights reserved. empiric antibiotic regimen to include coverage for resistant Gramnegative, Gram-positive, and anaerobic bacteria. In the clinically unstable child, nonbacterial etiologies such as fungi and viruses should also be considered.

Question

When can empiric antibiotics be discontinued in patients with low- and high-risk FN?

Recommendation

Discontinue empiric antibiotics in patients who have negative blood cultures at 48 hours, who have been afebrile for at least 24 hours, and who have evidence of marrow recovery (1C; strong recommendation, low-quality evidence). Consider discontinuation of empiric antibiotics at 72 hours in low-risk patients who have negative blood cultures and who have been afebrile for at least 24 hours, irrespective of marrow recovery status, as long as careful follow-up is ensured (2B; weak recommendation, moderate-quality evidence).

Explanation

Appropriate cessation of antimicrobials is important to minimize exposure to unnecessary antibiotics. Data Supplement 8 summarizes the pediatric observational and randomized trials that describe outcomes with cessation of antibiotics.⁷⁴⁻⁹³

When pediatric studies were stratified by the status of bone marrow recovery at the time of antibiotic discontinuation, the pooled incidence of recurrent fever was 1% (95% CI, 0.1% to 5%) in children with definite marrow recovery, 5% (95% CI, 3% to 9%) where marrow recovery was not required, and 14% (95% CI, 5% to 36%) where there was no evidence of marrow recovery. Consequently, empiric antibiotics should be discontinued in patients who are clinically well with negative blood cultures who have been afebrile for at least 24 hours and who have evidence of bone marrow recovery. The pediatric studies did not set threshold criteria for evidence of marrow recovery,^{75,80,83,85,86} but the Panel suggests that an absolute neutrophil count \geq 100/uL postnadir is reasonable.

Pediatric patients in whom antibiotics were discontinued irrespective of bone marrow recovery were more likely to demonstrate recurrent fever and, less frequently, bacterial infection (incidence, 2%; 95% CI, 0.1% to 5%). No bacterial infectious deaths were identified among low-risk patients. One RCT⁷⁷ randomly assigned low-risk patients to either stopping or continuing antibiotics on day 3 irrespective of bone marrow status and found no difference in outcome and no infectious deaths. However, *Enterobacter aerogenes* bacteremia occurred in one child in the group who stopped antibiotics early. Thus, discontinuation of empiric antibiotics in low-risk patients at 72 hours irrespective of bone marrow status may be appropriate as long as careful follow-up is ensured.

The optimal duration of empiric antibiotics for high-risk patients with sustained bone marrow suppression is uncertain. In 1979, Pizzo et al⁷⁶ randomly assigned 33 high-risk patients age 1 to 30 years who were afebrile and neutropenic on day 7 to either continuing or stopping antibiotics. Of the 17 patients who discontinued antibiotics, seven developed infectious sequalae, and two died as a result of *Escherichia coli* bacteremia.⁷⁶ Because this single study was conducted more than 30 years ago, the optimal duration of antibiotic administration in high-risk patients represents a research gap.

SECTION 3: EMPIRIC ANTIFUNGAL TREATMENT

Question

What clinical parameters can classify pediatric patients with persistent FN as high risk or low risk for invasive fungal disease (IFD)?

Recommendation

Patients at high risk for IFD are those with acute myeloid leukemia, relapsed acute leukemia, those receiving highly myelosuppressive chemotherapy for other malignancies, and allogeneic HSCT recipients with persistent fever despite prolonged (\geq 96 hours) broadspectrum antibiotic therapy and expected prolonged neutropenia (>10 days). All others should be categorized as being at low risk for IFD (1B; strong recommendation, moderate-quality evidence).

Explanation

The risk stratification for IFD in children is based on underlying malignancy (higher risk in acute myeloid leukemia and relapsed acute leukemia) or type of HSCT (higher risk in unrelated cord blood and matched unrelated donor transplantation) as well as on certain clinical and laboratory factors (higher risk in patients with severe and prolonged neutropenia, mucositis, CVC, steroid exposure, and elevated CRP on day 4 of FN).^{1,94-101} IFD low-risk patients include children with standard-risk acute lymphoblastic leukemia, lymphoma, and most solid tumors,^{95,102,103} although IFDs have been described in these patients.¹⁰⁵ Importantly, environmental factors such as proximity to construction work also influence the risk for invasive aspergillosis.^{105,106}

Question

What clinical features, laboratory tests, imaging studies, and procedures (such as bronchoalveolar lavage [BAL] and biopsy) are useful to identify a fungal etiology for persistent/recurrent FN despite broadspectrum antibiotics?

Recommendation

Consider prospective monitoring of serum galactomannan (GM) twice per week in IFD high-risk hospitalized children for early diagnosis of invasive aspergillosis (2B; weak recommendation, moderate-quality evidence). In IFD low-risk patients, do not implement routine GM screening (1C; strong recommendation, lowquality evidence). Consider GM in BAL and cerebrospinal fluid to support the diagnosis of pulmonary or CNS aspergillosis (2C; weak recommendation, low-quality evidence). In children, do not use β -D-glucan (BG) testing for clinical decisions until further pediatric evidence has accumulated (1C; strong recommendation, lowquality evidence). In IFD high-risk children with persistent FN beyond 96 hours, perform evaluation for IFD. Evaluation should include computed tomography (CT) of the lungs and targeted imaging of other clinically suspected areas of infection (1B; strong recommendation, moderate-quality evidence). Consider CT of the sinuses in children 2 years of age or older (2C; weak recommendation, low-quality evidence).

Explanation

GM. A total of 10 pediatric studies evaluated serum GM as a mycologic criterion¹⁰⁷ of IFD,¹⁰⁸⁻¹¹⁴ mostly in the setting of serial

screening in IFD high-risk patients (Data Supplement 9). The combined sensitivity and specificity of the five pediatric studies that included adequate information for individual patients and used European Organisation for Research and Treatment in Cancer/Mycoses Study Group IFD diagnostic criteria^{109-112,115} were 0.76 (95% CI, 0.62 to 0.87) and 0.86 (95% CI, 0.68 to 0.95), respectively, favorably comparing with the results from a meta-analysis of GM testing in adults (0.73; 95% CI, 0.46 to 0.61 and 0.90; 95% CI, 0.88 to 0.92, respectively).¹¹⁶ Although the diagnostic properties of GM testing are adequate in children, the overall effectiveness of routine GM screening in children to improve clinical outcomes is unclear, leading to a weak recommendation. It is important to note that some antibacterial compounds (such as piperacillin-tazobactam) may cause false-positive GM results in pediatric and adult patients.

In terms of GM testing in body fluids other than serum, a small pediatric study corroborated the results of a retrospective study of 99 adult IFD high-risk hematology patients¹¹⁷ and suggested that BAL GM is a potentially valuable adjunctive diagnostic tool in addition to conventional microbiologic and radiologic studies.¹¹⁸ Similarly, limited data suggest that detection of GM in cerebrospinal fluid can support the diagnosis of invasive aspergillosis in the CNS in both children and adults.^{119,120}

BG. BG is included in the revised definitions of IFD by the European Organisation for Research and Treatment in Cancer/Mycoses Study Group.¹⁰⁷ In contrast to adults in whom BG testing has demonstrated good diagnostic accuracy for early diagnosis of IFD,¹²¹ there are limited data in children.^{122,123} Furthermore, the optimal threshold for positivity of BG testing in children is unknown. Mean BG levels are slightly higher in immunocompetent uninfected children than in adults.¹²⁴ BG should not currently be used to guide pediatric clinical decision making.

Imaging studies. Prospective adult studies have demonstrated that CT detects pneumonia earlier than CXR, and systematic CT scans allow earlier diagnosis of invasive pulmonary aspergillosis with a resultant improvement in prognosis.^{125,126} The limited data on imaging studies in children with underlying malignancy and persistent FN¹²⁷⁻¹³⁰ demonstrate that radiographic findings in immunocompromised children with proven pulmonary IFD are often nonspecific.^{127,128} In particular, in children younger than 5 years of age, typical signs of pulmonary IFD (halo sign, air crescent sign, and cavities) are not seen in the majority of patients.

The role of routine sinus imaging (such as by CT) during prolonged FN is uncertain, and data on the frequency of accompanying symptoms of sinonasal IFD in children are scarce.^{131,132} Notably, children younger than 2 years of age have not had sufficient pneumatization of the sinus cavities, and thus, sinus imaging is rarely informative in this age range. Similarly, the role of routine abdominal imaging is uncertain, and imaging of abdominal lesions may be falsely negative in neutropenic children.¹³³

Diagnostic procedures in patients with positive laboratory studies and/or imaging. In children with positive GM or imaging studies that suggest IFD, antifungal treatment with a mold-active agent should be initiated, and further diagnostic investigation should be considered whenever possible (such as BAL and *trans*-bronchial or *trans*-thoracic biopsy in the case of pulmonary lesions).¹³⁴ However, there are no published pediatric data to identify the diagnostic procedure with the greatest yield relative to procedure-related risks in this setting.

Question

When should empiric antifungal therapy be initiated, what antifungal agents are appropriate, and when is it appropriate to discontinue empiric therapy?

Recommendation

In neutropenic IFD high-risk children, initiate empiric antifungal treatment for persistent or recurrent fever of unclear etiology that is unresponsive to prolonged (\geq 96 hours) broad-spectrum antibacterial agents (1C; strong recommendation, low-quality evidence). In neutropenic IFD low-risk children, consider empiric antifungal therapy in the setting of persistent FN (2C; weak recommendation, very low-quality evidence). Use either caspofungin or liposomal amphotericin B (L-AmB) for empiric antifungal therapy (1A; strong recommendation, high-quality evidence).

Explanation

Three prospective trials evaluated empiric antifungal therapy in children with persistent FN (Data Supplement 10).¹³⁵⁻¹³⁷ Caspofungin was as effective as L-AmB,¹³⁶ L-AmB was slightly more effective than amphotericin B deoxycholate (AmB-D),¹³⁵ and the efficacy of AmB-D was similar to that of amphotericin B colloidal dispersion.¹³⁷ Caspofungin was better tolerated than L-AmB, and L-AmB was less nephrotoxic than AmB-D. Results were consistent with those of much larger trials in adults.¹³⁸⁻¹⁴⁰ Thus, either caspofungin or L-AmB should be used for empiric antifungal therapy in children. However, AmB-D may be considered as an alternative in settings with limited resources.

Adult guidelines recommend empiric antifungal therapy be initiated in IFD high-risk neutropenic patients after 96 hours of fever in the setting of broad-spectrum antibiotics.¹ Because of the lack of pediatric-specific data, it is reasonable to recommend a similar approach in children. Although there are almost no data to guide cessation of antifungal therapy, the Panel agrees that empiric antifungal therapy should be continued until resolution of neutropenia (absolute neutrophil count > 100-500/uL) in the absence of documented or suspected IFD.

Preemptive antifungal therapy has been accepted as an alternative to empiric antifungal therapy in a subset of IFD high-risk adult neutropenic patients.¹ There are no studies evaluating this approach in children. Although a preemptive approach may be feasible in centers with adequate experience and facilities, research describing the safety and effectiveness of this approach is needed.

DISCUSSION

We have created an evidence-based guideline for the management of pediatric FN. Some recommendations are similar to those of adult guidelines, such as choice of empiric antibacterials and criteria for their modification. Some similar recommendations have benefitted from a pediatric-specific focus, such as consideration of outpatient management and oral antibacterial therapy. However, there are key distinctions. For example, the proposed risk stratification schemas are pediatric specific, and a number of diagnostic tools such as BG testing have pediatric-specific limitations. These factors have an important impact on the care of pediatric patients. Future iterations of this

8 © 2012 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 Americanfr@orcie492df50lift@aB9ncology. All rights reserved. usefulness and areas for improvement. CMAJ 182:

Grading quality of evidence and strength of recom-

mendations in clinical practice guidelines: Part 1 of

3-An overview of the GRADE approach and grad-

ing quality of evidence about interventions. Allergy

Predicting the risk of bacteremia in children with

fever and neutropenia. J Clin Oncol 14:919-924,

Evaluation of risk prediction criteria for episodes of

febrile neutropenia in children with cancer. J Pediatr

proposed score for predicting severe infection complica-

tions in children with chemotherapy-induced febrile neu-

Prospective, multicenter evaluation of risk factors

associated with invasive bacterial infection in chil-

dren with cancer, neutropenia, and fever. J Clin

fication of children presenting with fever in chemo-

therapy-induced neutropenia at low risk for severe

bacterial infection. Med Pediatr Oncol 41:436-443,

dicting adverse events in children with fever and

chemotherapy-induced neutropenia: The prospec-

tive multicenter SPOG 2003 FN study. J Clin Oncol

of electronic data for model validation and refine-

ment: Bacteremia risk in children with fever and

neutropenia. J Pediatr Hematol Oncol 24:256-262,

Successful introduction and audit of a step-down

oral antibiotic strategy for low risk paediatric febrile

19. Dommett R, Geary J, Freeman S, et al:

18. Madsen K, Rosenman M, Hui S, et al: Value

17. Ammann RA, Bodmer N, Hirt A, et al: Pre-

16. Ammann RA, Hirt A, Lüthy AR, et al: Identi-

tropenia. J Pediatr Hematol Oncol 28:665-670, 2006

Hematol Oncol 24:38-42, 2002

Oncol 19:3415-3421, 2001

28:2008-2014, 2010

12. Rackoff WR, Gonin R, Robinson C, et al:

13. Alexander SW, Wade KC, Hibberd PL, et al:

14. Rondinelli PI, Ribeiro Kde C, de Camargo B: A

15. Santolaya ME, Alvarez AM, Becker A, et al:

11. Brozek JL, Akl EA, Alonso-Coello P, et al:

1045-1052, 2010

64:669-677, 2009

1996

2003

2002

guideline will need to incorporate evolving and emerging evidence as research is conducted in pediatric FN.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Thomas Lehrnbecher, Astellas Pharma (C), Gilead Sciences (C), Merck (C); Elio Castagnola, Astellas Pharma (C), Gilead Sciences (C), Pfizer (C); Andreas H. Groll, Astellas Pharma (C), Gilead Sciences (C), Merck (C), Schering-Plough (C); William J. Steinbach, Astellas Pharma (C), Merck (C); Theoklis Zaoutis, Astellas Pharma (C), Cubist Pharmaceuticals (C), HemoCue (C), Merck (C), Pfizer (C) Stock Ownership: None Honoraria: Thomas Lehrnbecher, Gilead Sciences, Merck, Pfizer; Elio Castagnola, Astellas Pharma, Gilead Sciences, Merck;

REFERENCES

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93, 2011

2. Bucaneve G, Castagnola E, Viscoli C, et al: Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer 5:5-12, 2007 (suppl)

3. Drgona L, Paul M, Bucaneve G, et al: The need for aminoglycosides in combination with β -lactams for high-risk, febrile neutropaenic patients with leukaemia. Eur J Cancer 5:13-22, 2007 (suppl)

 Cometta A, Marchetti O, Calandra T: Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. Eur J Cancer 5:23-31, 2007 (suppl)

5. Marchetti O, Cordonnier C, Calandra T: Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer 5:32-42, 2007 (suppl)

6. National Comprehensive Cancer Network: NCCN Guidelines for Supportive Care: Prevention and Treatment of Cancer-Related Infections (Version 2.2011). http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp

7. de Naurois J, Novitzky-Basso I, Gill MJ, et al: Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21:v252-v256, 2010 (suppl 5)

8. Sung L, Phillips R, Lehrnbecher T: Time for paediatric febrile neutropenia guidelines: Children are not little adults. Eur J Cancer 47:811-813, 2011

9. Oxman AD, Fretheim A, Schünemann HJ: Improving the use of research evidence in guideline development: Introduction. Health Res Policy Syst 4:12, 2006

10. Brouwers MC, Kho ME, Browman GP, et al: Development of the AGREE II, part 1: Performance,

Andreas H. Groll, Astellas Pharma, Gilead Sciences, Merck, Pfizer, Schering-Plough, Cephalon, Zeneus Pharma; William J. Steinbach, Pfizer; Theoklis Zaoutis, Merck, Pfizer, Astellas Pharma **Research Funding:** Brian Fisher, Pfizer; Elio Castagnola, Pfizer; Andreas H. Groll, Gilead Sciences, Merck; William J. Steinbach, Astellas Pharma, Merck; Theoklis Zaoutis, Merck **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Fabianne Carlesse, Brian Fisher, Hana Hakim, Elio Castagnola, L. Lee Dupuis, Andreas H. Groll, Aditya Gaur, Sérgio Petrilli, Theoklis Zaoutis, Lillian Sung

Provision of study materials or patients: All authors

Collection and assembly of data: Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Frank Alvaro, Fabianne Carlesse, Brian Fisher, Hana Hakim, Maria Santolaya, Elio Castagnola, Andreas H. Groll, Aditya Gaur, Sérgio Petrilli, Milena Villarroel, Theoklis Zaoutis, Lillian Sung

Data analysis and interpretation: Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Frank Alvaro, Hana Hakim, Maria Santolaya, Elio Castagnola, Bonnie L. Davis, L. Lee Dupuis, Faith Gibson, Andreas H. Groll, Aditya Gaur, Ajay Gupta, Rejin Kebudi, William J. Steinbach, Milena Villarroel, Lillian Sung

Manuscript writing: All authors

Final approval of manuscript: All authors

neutropaenia in a UK, multicentre, shared care setting. Eur J Cancer 45:2843-2849, 2009

20. Santolaya ME, Alvarez AM, Avilés CL, et al: Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis 35: 678-683, 2002

21. Macher E, Dubos F, Garnier N, et al: Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer 55:662-667, 2010

22. Miedema KG, de Bont ES, Oude Nijhuis CS, et al: Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol 29:e182-e184, 2011

23. Agyeman P, Aebi C, Hirt A, et al: Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 30:e114-e119, 2011

24. Ammann RA, Aebi C, Hirt A, et al: Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center, 1993-2001. Support Care Cancer 12:826-832, 2004

25. Baorto EP, Aquino VM, Mullen CA, et al: Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 92:909-913, 2001

26. Hakim H, Flynn PM, Srivastava DK, et al: Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53-59, 2010

27. Hann I, Viscoli C, Paesmans M, et al: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies—International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580-588, 1997

28. Jones GR, Konsler GK, Dunaway RP, et al: Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol 13:217-229, 1996

9

© 2012 by American Society of Clinical Oncology Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 AmericanfiSorcie42/20f50linteab9ncology. All rights reserved. **30.** Lucas KG, Brown AE, Armstrong D, et al: The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77:791-798, 1996

31. Paganini HR, Aguirre C, Puppa G, et al: A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 109:2572-2579, 2007

32. Tezcan G, Kupesiz A, Ozturk F, et al: Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol 23:217-229, 2006

33. West DC, Marcin JP, Mawis R, et al: Children with cancer, fever, and treatment-induced neutropenia: Risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care 20:79-84, 2004

34. Phillips B, Wade R, Stewart LA, et al: Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 46:2950-2964, 2010

35. Toll DB, Janssen KJ, Vergouwe Y, et al: Validation, updating and impact of clinical prediction rules: A review. J Clin Epidemiol 61:1085-1094, 2008

36. Phillips R, Lehrnbecher T, Alexander S, et al: Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 7:e38300, 2012

37. Scheinemann K, Ethier MC, Dupuis LL, et al: Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer 18:913-919, 2010

38. DesJardin JA, Falagas ME, Ruthazer R, et al: Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 131:641-647, 1999

39. Chen WT, Liu TM, Wu SH, et al: Improving diagnosis of central venous catheter-related blood-stream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital. J Infect 59:317-323, 2009

40. Adamkiewicz TV, Lorenzana A, Doyle J, et al: Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 18:556-558, 1999

41. Raad I, Hanna HA, Alakech B, et al: Differential time to positivity: A useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 140:18-25, 2004

42. Handrup MM, Moller JK, Schroder H: Catheter-related bloodstream infections in children with cancer admitted with fever. Presented at the 42nd Congress of the International Society of Pediatric Oncology, Boston, MA, October 21-24, 2010

43. Barriga FJ, Varas M, Potin M, et al: Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 28:196-200, 1997

44. O'Grady NP, Alexander M, Burns LA, et al: Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 39: S1-S34, 2011 (suppl 1) **45.** Wilson ML, Mitchell M, Morris AJ, et al: Principles and Procedures for Blood Cultures: Approved Guideline—CLSI Document M47-A. Wayne, PA, Clinical and Laboratory Standards Institute, 2007

46. Isaacman DJ, Karasic RB, Reynolds EA, et al: Effect of number of blood cultures and volume of blood on detection of bacteremia in children. J Pediatr 128:190-195, 1996

47. Kellogg JA, Manzella JP, Bankert DA: Frequency of low-level bacteremia in children from birth to fifteen years of age. J Clin Microbiol 38:2181-2185, 2000

48. Connell TG, Rele M, Cowley D, et al: How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 119:891-896, 2007

49. Gaur AH, Giannini MA, Flynn PM, et al: Optimizing blood culture practices in pediatric immunocompromised patients: Evaluation of media types and blood culture volume. Pediatr Infect Dis J 22:545-552, 2003

50. Klaassen IL, de Haas V, van Wijk JA, et al: Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 56:868-870, 2011

51. Mori R, Yonemoto N, Fitzgerald A, et al: Diagnostic performance of urine dipstick testing in children with suspected UTI: A systematic review of relationship with age and comparison with microscopy. Acta Paediatr 99:581-584, 2010

52. Sickles EA, Greene WH, Wiernik PH: Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715-719, 1975

53. Feusner J, Cohen R, O'Leary M, et al: Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol 6:1699-1702, 1988

54. Katz JA, Bash R, Rollins N, et al: The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia. Cancer 68: 940-943, 1991

55. Korones DN, Hussong MR, Gullace MA: Routine chest radiography of children with cancer hospitalized for fever and neutropenia: Is it really necessary? Cancer 80:1160-1164, 1997

56. Renoult E, Buteau C, Turgeon N, et al: Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 43:224-228, 2004

57. Phillips R, Wade R, Riley R, et al: Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. J Paediatr Child Health, 2011

58. Furno P, Bucaneve G, Del Favero A: Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2:231-242, 2002

59. Paul M, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 326: 1111, 2003

60. Manji A, Lehrnbecher T, Dupuis LL, et al: A systematic review and meta-analysis of antipseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer [epub ahead of print on December 6, 2011]

61. Manji A, Lehrnbecher T, Dupuis LL, et al: A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia. Pediatr Infect Dis J 31:353-358, 2012

62. Paul M, Yahav D, Bivas A, et al: Antipseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: Comparison of beta-lactams. Cochrane Database Syst Rev 11: CD005197, 2010

63. Kim PW, Wu YT, Cooper C, et al: Metaanalysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51: 381-389, 2010

64. Marron A, Carratalà J, Alcaide F, et al: High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 47:87-91, 2001

65. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al: Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: A meta-analysis of randomised controlled trials. Lancet Infect Dis 5:431-439, 2005

66. Speyer E, Herbinet A, Vuillemin A, et al: Agreement between children with cancer and their parents in reporting the child's health-related quality of life during a stay at the hospital and at home. Child Care Health Dev 35:489-495, 2009

67. Teuffel O, Amir E, Alibhai SM, et al: Costeffectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 127: e279-e286, 2011

68. Teuffel O, Ethier MC, Alibhai SM, et al: Outpatient management of cancer patients with febrile neutropenia: A systematic review and metaanalysis. Ann Oncol 22:2358-2365, 2011

69. Ahmed N, El-Mahallawy HA, Ahmed IA, et al: Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatr Blood Cancer 49:786-792, 2007

70. Santolaya ME, Alvarez AM, Avilés CL, et al: Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22:3784-3789, 2004

71. Manji A, Beyene J, Dupuis LL, et al: Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children: A systematic review of prospective trials. Support Care Cancer 20:1135-1145, 2012

72. Vidal L, Paul M, Ben-Dor I, et al: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 4:CD003992, 2004

73. Cometta A, Kern WV, De Bock R, et al: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37:382-389, 2003

74. Oude Nijhuis C, Kamps WA, Daenen SM, et al: Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23:7437-7444, 2005

75. Aquino VM, Buchanan GR, Tkaczewski I, et al: Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 28:191-195, 1997

76. Pizzo PA, Robichaud KJ, Gill FA, et al: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 67:194-200, 1979

77. Santolaya ME, Villarroel M, Avendaño LF, et al: Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study. Clin Infect Dis 25:92-97, 1997

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OF TORONTO on September 17, 2012 Copyright © 2012 Americanfr@orcie492df50lift@2aB9ncology. All rights reserved.

Pediatric Fever and Neutropenia Guidelines

78. Wacker P, Halperin DS, Wyss M, et al: Early hospital discharge of children with fever and neutropenia: A prospective study. J Pediatr Hematol Oncol 19:208-211, 1997

79. Cohen KJ, Leamer K, Odom L, et al: Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia: A preliminary prospective trial. J Pediatr Hematol Oncol 17:325-330, 1995

80. Bash RO, Katz JA, Cash JV, et al: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196, 1994

81. Hodgson-Viden H, Grundy PE, Robinson JL: Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 5:10, 2005

82. Lehrnbecher T, Stanescu A, Kühl J: Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 30:17-21, 2002

83. Griffin TC, Buchanan GR: Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 121:28-33, 1992

84. Kaplan AH, Weber DJ, Davis L, et al: Short courses of antibiotics in selected febrile neutropenic patients. Am J Med Sci 302:353-354, 1991

85. Mullen CA, Buchanan GR: Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 8:1998-2004, 1990

86. Aquino VM, Tkaczewski I, Buchanan GR: Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 25:74-78, 1997

87. Slobbe L, Waal L, Jongman LR, et al: Threeday treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: A prospective observational safety study. Eur J Cancer 45:2810-2817, 2009

88. Cornelissen JJ, Rozenberg-Arska M, Dekker AW: Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 21:1300-1302, 1995

89. de Marie S, van den Broek PJ, Willemze R, et al: Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 12:897-906, 1993

90. Joshi JH, Schimpff SC, Tenney JH, et al: Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 76:450-457, 1984

91. Björnsson S, Preisler H, Henderson ES: A study of antibiotic therapy in fever of unknown origin in neutropenic cancer patients. Med Pediatr Oncol 3:379-385, 1977

92. Mahendra P, Jacobson SK, Ager S, et al: Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients. Acta Haematol 96:64-67, 1996

93. Tomiak AT, Yau JC, Huan SD, et al: Duration of intravenous antibiotics for patients with neutropenic fever. Ann Oncol 5:441-445, 1994

94. Groll AH, Kurz M, Schneider W, et al: Fiveyear-survey of invasive aspergillosis in a paediatric cancer centre: Epidemiology, management and long-term survival. Mycoses 42:431-442, 1999 **95.** Zaoutis TE, Heydon K, Chu JH, et al: Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711-e716, 2006

96. Leahey AM, Bunin NJ, Belasco JB, et al: Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Pediatr Oncol 34:313-318, 2000

97. Mor M, Gilad G, Kornreich L, et al: Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 56:1092-1097, 2011

98. Rosen GP, Nielsen K, Glenn S, et al: Invasive fungal infections in pediatric oncology patients: 11year experience at a single institution. J Pediatr Hematol Oncol 27:135-140, 2005

99. Castagnola E, Cesaro S, Giacchino M, et al: Fungal infections in children with cancer: A prospective, multicenter surveillance study. Pediatr Infect Dis J 25:634-639, 2006

100. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al: Invasive fungal infections in pediatric bone marrow transplant recipients: Single center experience of 10 years. Bone Marrow Transpl 26:999-1004, 2000

101. Villarroel M, Avilés CL, Silva P, et al: Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: A prospective multicenter evaluation. Pediatr Infect Dis J 29:816-821, 2010

102. Afzal S, Ethier MC, Dupuis LL, et al: Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 28:1064-1068, 2009

103. Haupt R, Romanengo M, Fears T, et al: Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: A 12-year experience at a single Italian institution. Eur J Cancer 37:2413-2419, 2001

104. Grigull L, Beier R, Schrauder A, et al: Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses 46:441-446, 2003

105. Panackal AA, Li H, Kontoyiannis D, et al: Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 50:1588-1597, 2010

106. Haiduven D: Nosocomial aspergillosis and building construction. Med Mycol 47:S210-S216, 2009 (suppl 1)

107. De Pauw B, Walsh TJ, Donnelly JP, et al: Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. Clin Infect Dis 46:1813-1821, 2008

108. Rohrlich P, Sarfati J, Mariani P, et al: Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: Early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 15:232-237, 1996

109. El-Mahallawy HA, Shaker HH, Ali Helmy H, et al: Evaluation of pan-fungal PCR assay and aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 44:733-739, 2006

110. Hovi L, Saxen H, Saarinen-Pihkala UM, et al: Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer 48:28-34, 2007

111. Steinbach WJ, Addison RM, McLaughlin L, et al: Prospective aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell trans-

plant recipients. Pediatr Infect Dis J 26:558-564, 2007

112. Hayden R, Pounds S, Knapp K, et al: Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 27:815-819, 2008

113. Armenian SH, Nash KA, Kapoor N, et al: Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol 31:920-926, 2009

114. Castagnola E, Furfaro E, Caviglia I, et al: Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin Microbiol Infect 16: 1197-1203, 2010

115. Challier S, Boyer S, Abachin E, et al: Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 42:844-846, 2004

116. Pfeiffer CD, Fine JP, Safdar N: Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 42:1417-1427, 2006

117. Maertens J, Maertens V, Theunissen K, et al: Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 49:1688-1693, 2009

118. Desai R, Ross LA, Hoffman JA: The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 28:283-286, 2009

119. Roilides E, Pavlidou E, Papadopoulos F, et al: Cerebral aspergillosis in an infant with corticosteroidresistant nephrotic syndrome. Pediatr Nephrol 18:450-453, 2003

120. Viscoli C, Machetti M, Gazzola P, et al: Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 40: 1496-1499, 2002

121. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al: β -D-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. Clin Infect Dis 52:750-770, 2011

122. Mularoni A, Furfaro E, Faraci M, et al: High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol 17:882-883, 2010

123. Zhao L, Tang JY, Wang Y, et al: Value of plasma β -glucan in early diagnosis of invasive fungal infection in children. Chin J Contemp Pediatr 11: 905-908, 2009

124. Smith PB, Benjamin DK Jr, Alexander BD, et al: Quantification of 1,3-beta-D-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 14:924-925, 2007

125. Heussel CP, Kauczor HU, Heussel GE, et al: Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed tomography. J Clin Oncol 17:796-805, 1999

126. Caillot D, Casasnovas O, Bernard A, et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15:139-147, 1997

127. Taccone A, Occhi M, Garaventa A, et al: CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 23:177-180, 1993

128. Burgos A, Zaoutis TE, Dvorak CC, et al: Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121:e1286-e1294, 2008

129. Archibald S, Park J, Geyer JR, et al: Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J 20:5-10, 2001

130. Agrawal AK, Saini N, Gildengorin G, et al: Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies? Pediatr Blood Cancer 57:620-624, 2011

131. Sörensen J, Becker M, Porto L, et al: Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses 49:31-36, 2006 (suppl 1)

132. Rassi SJ, Melkane AE, Rizk HG, et al: Sinonasal mucormycosis in immunocompromised pediatric patients. J Pediatr Hematol Oncol 31:907-910, 2009

133. Flynn PM, Shenep JL, Crawford R, et al: Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients, Clin Infect Dis 20:964-970, 1995

134. Bochennek K, Abolmaali N, Wittekindt B, et al: Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin Microbiol Infect 12:199-201, 2006

135. Prentice HG, Hann IM, Herbrecht R, et al: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711-718, 1997

136. Maertens JA, Madero L, Reilly AF, et al: A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415-420, 2010

137. Sandler ES, Mustafa MM, Tkaczewski I, et al: Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 22:242-246, 2000

138. Walsh TJ. Teppler H. Donowitz GR. et al: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402, 2004

139. White MH, Bowden RA, Sandler ES, et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296-302, 1998

140. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764-771, 1999

Affiliations

Thomas Lehrnbecher, Johann Wolfgang Goethe University, Frankfurt; Andreas H. Groll, University Children's Hospital Muenster, Muenster, Germany; Robert Phillips, Leeds General Infirmary, Leeds, and University of York, York; Faith Gibson, Great Ormond St Hospital and London South Bank University, London, United Kingdom; Sarah Alexander, L. Lee Dupuis, and Lillian Sung, The Hospital for Sick Children, Toronto, Ontario, Canada; Frank Alvaro, John Hunter Children's Hospital, Newcastle, New South Wales, Australia; Fabianne Carlesse and Sérgio Petrilli, Federal University of São Paulo, São Paulo, Brazil; Brian Fisher and Theoklis Zaoutis, The Children's Hospital of Philadelphia, Philadelphia, PA; Hana Hakim and Aditya Gaur, St Jude Children's Research Hospital, Memphis, TN; Maria Santolaya and Milena Villarroel, Hospital Luis Calvo Mackenna and Universidad de Chile, Santiago, Chile; Elio Castagnola, Istituto Giannina Gaslini, Genova, Italy; Bonnie L. Davis, High Tor, Nassau, Bahamas; Ajay Gupta, Institute Rotary Cancer Hospital and All India Institute of Medical Sciences, New Delhi, India; Rejin Kebudi, Istanbul University, Istanbul, Turkey; and William J. Steinbach, Duke University Medical Center, Durham, NC.

Acknowledgment

We thank Tanya Hesser for her excellent administrative assistance.